Drug Design and Discovery in Alzheimer''s Disease includes expert reviews of recent developments in Alzheimer''s disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.- Edited and written by leading experts in Alzheimer''s disease (AD) and other neurodegenerative disease drug development- Describes existing drugs for AD and current molecular understanding of the condition- Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Drug Design and Discovery in Alzheimer''s Disease includes expert reviews of recent developments in Alzheimer''s disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.- Edited and written by leading experts in Alzheimer''s disease (AD) and other neurodegenerative disease drug development- Describes existing drugs for AD and current molecular understanding of the condition- Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Drug Design and Discovery in Alzheimer''s Disease includes expert reviews of recent developments in Alzheimer''s disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.- Edited and written by leading experts in Alzheimer''s disease (AD) and other neurodegenerative disease drug development- Describes existing drugs for AD and current molecular understanding of the condition- Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets